Nephropathy In Type Research Articles

Astaxanthin delayed the pathogenesis of diabetic nephropathy in type 1 diabetic rats

This study was designed to investigate the protective effects of Astaxanthin (AST) in rats with diabetes mellitus (DM) induced by streptozotocin. SD rats were divided into control group (n = 5, only received normal saline), DM group (n = 8) and AST + DM group (n = 8; AST: 50 mg/kg/day). DM rats were induced by intraperitoneal injection of streptozocin (STZ, 65 mg/kg). Blood glucose level and body weight were determined at weeks 0, 2, 4, 6 and 8, respectively. At week 8, kidney function was determined, together with expression of P53 and dynamin-related protein-1 (Drp1) by Western blot analysis and immunofluorescence. AST led to increase of body weight in rats with DM. AST + DM group showed a significant decrease in blood glucose level at week 4 compared with DM group (P < 0.05). AST improved renal function and significantly reduced expression of P53 and Drp1 in DM rats. In addition, AST can effectively reduce the blood glucose in DM rats, and delayed the pathogenesis of diabetic nephropathy. Such delay mediated by AST may be associated with the downregulation of Drp1 and P53.

Evaluation of Mir 29c-3p and Mir 31-5p Serum Values in Predicting Nephropathy in Type 2 Diabetic Patients

Evaluation of Mir 29c-3p and Mir 31-5p Serum Values in Predicting Nephropathy in Type 2 Diabetic Patients

Role of kidney injury molecule 1 and nephrin as biomarkers for diagnosis of nephropathy in type 2 diabetes mellitus

Role of kidney injury molecule 1 and nephrin as biomarkers for diagnosis of nephropathy in type 2 diabetes mellitus

Overview of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients at Royal Prima Hospital Medan Indonesia

Diabetes Mellitus (DM) is a chronic disease characterized by blood glucose (blood sugar) levels exceeding normal. Diabetic nephropathy is a chronic microvascular complication that often occurs in diabetics. This study presents a picture of diabetic nephropathy in type 2 DM patients at the Royal Prima Hospital in Medan. This research is a type of descriptive research. The sample from this study was the total data of patients suffering from diabetic nephropathy who met the inclusion and exclusion criteria at Royal Prima Hospital from January 1, 2020 – to December 31, 2020. The inclusion criteria for the subjects of this study were complete patient medical records, type 2 diabetes patients, urinalysis tests. (proteinuria ≥ +2), renal function examination exceeds normal values, blood urea, and creatinine. The mean age of diabetic nephropathy patients was 57.52 years and the majority were 62 men (50.8%). The average picture of urea levels in diabetic nephropathy patients is 51.8 and the average creatinine level is 1.48. The majority of patients with diabetic nephropathy do not have proteinuria. And the average blood sugar level is 267 mg/dL. In conclusion, the incidence of diabetic nephropathy is highest in patients aged 57 years. The mean value of urea level is 51.80 mg/dl, creatinine value is 1.48 mg/dl, and the average blood sugar level is 267 mg/dl. Most proteinuria was in the negative category of as many as 107 people (87%).

The association between EKG abnormalities and the development of microalbuminuria in type 2 diabetes.

Microalbuminuria is associated with both with chronic kidney disease and various cardiovascular abnormalities. Given the common use of electrocardiograms (EKGs) in diagnosing cardiovascular dysfunction, this study is analyzing the relationship between EKG abnormalities and diabetic nephropathy in type 2 diabetes mellitus (DM) patients. The enrollments of this study were from the 10-year follow-up data (2003–2012) of the Diabetes Management through an Integrated Delivery System project. All study subjects underwent at least 1 EKG measurement. The urinary microalbuminuria was recorded annually. The logistic regression model was used to evaluate the association between EKG abnormalities and the occurrence of diabetic nephropathy in type 2 DM patients. The total of 1189 patients with type 2 DM are included in this study and a total of 552 patients had microalbuminuria during a 10-year follow-up. A significantly higher odds ratio of microalbuminuria occurrence (4.85) was found in the patients with premature supraventricular contraction or tachycardia compared to those without EKG abnormalities. The odds ratios of microalbuminuria occurrence were 1.00, 2.43, 2.64, and 2.98, respectively, for patients with insulin resistance in the Q (quartile) 1(as the reference), Q2, Q3, and Q4, respectively. Our findings can serve as a reference for the association between EKG abnormalities and the development of microalbuminuria in type 2 diabetes.

Abstract #1082277: Urinary Albumin Creatinine Ratio Had No Significant Association With Retinopathy in Individuals With Type 1 Diabetes Mellitus

The relationship between diabetic retinopathy (DR) and nephropathy in type 1 diabetes mellitus (T1DM) is controversial. This study tried to assess the correlation between the spot urinary albumin creatinine ratio (UACR) as a parameter for diabetic nephropathy with DR in individuals with T1DM in Basrah-Southern Iraq.

Correlation of glycosylated hemoglobin with urinary albuminuria for early detection and progression of nephropathy in patients with type 2 diabetes millitus

diabetic nephropathy is a one of the most leading disorder in patients with type 2 diabetes mellitus. Urinary albuminuria used for detection of nephropathy in type 2 diabetes mellitus but its not an a sensitive and specific biomarker for DN. Recent studies found some of the sensitive and specific biomarker for early detection and progression of nephropathy in type 2 diabetes mellitus patients.A total 150 subjects included in the present study in that 100 patients diagnosed with type 2 diabetes mellitus and 50 healthy controls. All the subjects included after informed consent and blood, urine samples were collected from the all the subjects. FBS, PPBS, Urea, Creatinine, Uric acid, HbA1C and Urinary Albumin was analysed by using laboratory standard methods.statistically elevated levels of plasma FBS, PPBS, HbA1C in both the groups of type 2 diabetes mellitus when compared to healthy controls. Serum Urea, Creatinine and Uric Acid levels elevated in type 2 diabetes mellitus with microalbuminuria when compared to other two groups of study subjects. The Glycosylated hemoglobin positively correlated with urinary microalbuminuria in patients with two groups of type 2 diabetes mellitus.This study suggest that the poor glycemic control leads to increased further complications in patients with type 2 diabetes mellitus. Continuous monitoring of HbA1C and Urinary Albumin Levels were useful for progression and treatment of patients with type 2 diabetes mellitus.

Glucose control, diabetic retinopathy, and hemodialysis induction in subjects with normo-microalbuminuric type 2 diabetic patients with normal renal function followed for 15 years

AimsA high urinary albumin excretion (UAE) and low glomerular filtration rate (GFR) are risk factors for progressive renal function loss in type 2 diabetic patients. In addition, diabetic retinopathy (DR) is also a risk factor for progressive renal function decline in microalbuminuric type 2 diabetic patients. We aimed to elucidate the factors, including DR, associated with a more severe situation of diabetic nephropathy, i.e., hemodialysis (HD) induction in normo- and microalbuminuric type 2 diabetic patients without renal dysfunction. MethodsNormo- and microalbuminuric type 2 diabetic patients with normal renal function whose GFRs had been measured by iohexol injection in 1995–1997 and had been followed for over 5 years were analyzed (n = 199). HbA1c levels was divided into HbA1c ≥ 7.0 (n = 146) and <7.0 (n = 53) groups. The UAE levels were classified as normoalbuminuria (NA, n = 114) and microalbuminuria (MA, n = 85). Seventy-two patients had DR, and 96 had hypertension. Patients were followed up for 15.7 ± 6.0 years and frequency of and duration to the HD induction were evaluated. ResultsDuring the study period, 8 patients received HD induction. There were no remarkable differences in the rates of HD induction between patients with and without HbA1c ≥7.0, microalbuminuria, DR or hypertension. A Kaplan-Meier analysis revealed that HbA1c ≥7.0 (p = 0.037) and DR (p = 0.037) were associated with a significantly higher risk of HD induction than HbA1c <7.0 and no DR, respectively while albuminuria grade and hypertension were not associated with the risk of HD induction. There was significant negative correlation between HbA1c and annual decline rate of eGFR and annual decline rate of eGFR in the patients with prepro-proliferative DR (PDR) was significantly higher than that in the patients without DR. In the multivariate analysis, HbA1c and PDR showed significant relationships with the annual decline rate of eGFR. ConclusionsIt was reasonable that poorer glycemic control affected HD induction for 16 years follow-up. However, DR, especially PDR, should also be considered a substantial risk factor for HD induction although microalbuminuria and hypertension did not predict it at the early stage of diabetic nephropathy in type 2 diabetic patients with normal renal function.

Urinary IgG, serum CX3CL1 and miRNA-152-3p: as predictors of nephropathy in Egyptian type 2 diabetic patients

ABSTRACT The purpose of this study was to assess the role of urinary IgG, serum CX3CL1 and miRNA 152–3p levels as predictors of nephropathy in type 2 Egyptian diabetic patients. Sixty type 2 diabetic patients and twenty healthy controls were enrolled in a cross-sectional study. Then they were grouped into: three groups based upon urine albumin excretion (UAE). The expression of miRNA 152–3p in serum was measured using quantitative polymerase chain reaction (RTq-PCR). Serum CX3CL1 and urinary IgG concentrations were measured by ELISA. RTq-PCR revealed that serum miRNA-152-3p levels in patients were significantly higher than in controls. There was significant differences between group with normoalbuminuria and groups with diabetic nephropathy DN as regard to age, duration of nephropathy, Albumin/Creatinine ratio (A/C ratio), creatinine, urine IgG, CX3CL1 and HbA1c. In diabetic patients, there was a significant positive correlation between miRNA-152-3p levels and disease duration only as well as significant positive correlations between urinary IgG levels and age, disease duration, serum creatinine, A/C ratio, and urea. Positive correlation between serum fractalkine CX3CL1 level and age, duration of disease, urea, creatinine, A/C ratio, HbA1C and IgG in patient with DN. Serum CX3CL1 level, urinary IgG were significantly increased with the progress of nephropathy so these integrated biomarkers could be used as good predictors for early identification of nephropathy. But miRNA- 152-3p has inadequate prognostic indicator for ESRD progression.

Chemotactic Cytokine Receptor 5 Genetic Polymorphism in Diabetic Nephropathy of the Type 2 Diabetes Mellitus

Background and Aim: The inflammatory process can be involved in the pathophysiology of diabetic nephropathy (DN). One of the cytokine receptors in the inflammatory process is Chemotactic Cytokine Receptor 5 (CCR5), whose genetic variation can affect the incidence of DN in several populations in the world. This study aims to determine the proportion of CCR5 gene polymorphisms with DN in type 2 diabetes mellitus patients in Bali. Method: This study used a case-control design in 144 DNA samples of patients with type 2 diabetes mellitus. They were examined for the polymorphisms of the CCR5 gene by PCR-RFLP and then analyzed using Chi-Square statistical test. The p value &lt;0.05 was significant. Results: The proportion of males more than females in subjects with diabetic nephropathy (p = 0.000). Duration of diabetes and systolic blood pressure were higher in subjects with diabetic nephropathy (p = 0.002; p = 0.002) respectively. The polymorphisms of the CCR5 gene did not differ significantly in subjects with and without diabetic nephropathy (p = 0.224). Conclusions: Gender, systolic blood pressure and duration of diabetes were associated with diabetic nephropathy, while CCR5 gene polymorphisms were not significantly associated with diabetic nephropathy in type 2 diabetes mellitus patients in Bali.

Protective Effect of Keluoxin against Diabetic Nephropathy in Type 2 Diabetic Mellitus Models.

Diabetic nephropathy (DN) is a chronic kidney disease that develops in patients with diabetes mellitus (DM). Renal dysfunction and persistent proteinuria are the main clinical features of DN. Podocyte injury is an important cause of persistent proteinuria and diabetic kidney disease (DKD) progression. Traditional Chinese patent medicines can improve renal function by enhancing autophagy and promoting apoptosis. Keluoxin is a Chinese patent medicine that has the effect of invigorating qi and nourishing yin, activating blood, and eliminating blood stasis. Therefore, we hypothesized that Keluoxin may have a protective effect against diabetic nephropathy in rats with type 2 DM. Rats induced with diabetes through streptozocin (STZ) injection and a high-fat and high-sugar diet were treated with Keluoxin (0.63 g/kg/day) for 8 weeks, and renal function, biochemical indicators, and histopathological changes in renal tissues were observed. Immunofluorescence staining and western blot analysis were used to detect the expression of autophagy-related proteins. The results showed that Keluoxin reduced blood glucose and lipid levels, improved renal function, and alleviated renal histopathological changes in rats with DN. The therapeutic effect was similar to that of Irbesartan (15.6 mg/kg/day). It is inferred that the mechanism works through reducing the obstruction of downstream pathways of autophagy by improving the lysosomal degradation function and alleviating podocyte injury. This study demonstrates that Keluoxin could regulate autophagy in podocytes, alleviate kidney injury in rats with DN, and have a protective effect on renal function; its mechanism can thus be a potential therapy for DN.

Integrated lipidomics, transcriptomics and network pharmacology analysis to reveal the mechanisms of Danggui Buxue Decoction in the treatment of diabetic nephropathy in type 2 diabetes mellitus

Ethnopharmacological relevanceDanggui Buxue Decoction (DBT) is classical prescriptions, which contains two Traditional Chinese Medicines of Angelicae sinensis radix and Astragali radix. According to the preliminary work of our laboratory and numerous studies, it has been found that DBT has a therapeutic effect on diabetic nephropathy (DN). However, the mechanisms underlying its action remain unclear. Aim of the studyThe aim of this study was to evaluate the impact of DBT on kidney disease in diabetic mice and further explore its protective mechanism. MethodsDN mice model was induced by high-fat fodder and streptozotocin (STZ). Qualitative and quantitative analysis of 6 compounds in DBT was carried out by HPLC, including calycosin-7-glucoside, ferulic acid, ononin, calycosin, formononetin, and levostilide A. Hematoxylin-Eosin (HE) staining was used to determine the degree of kidney pathological damage. The UPLC-Q Exactive MS technique was used to analyze the lipids metabolism profile of kidneys samples and multiple statistical analysis methods were used to screen and identify biomarkers. Transcriptomics analyses were carried out using RNAseq. The possible molecular mechanism was unraveled by network pharmacology. ResultsThirty-one significantly altered lipid metabolites were identified in the model group comparing with the control group. DBT improved aberrant expression of several pathways related to lipidomics, including glycerophospholipid metabolism and sphingolipid metabolism. Comprehensive analysis indicated that DBT intervention reduced the content of Cers, phosphatidylethanolamines and phosphatidylcholines in mouse kidneys by downregulating the transcription level of Degs2 and Cers, reducing lipid accumulation and promoting Akt phosphorylation by upregulating the expression of Acers and Pdk1. Network pharmacology analysis showed that components in DBT, such as kaempferol, ferulic acid and astragaloside IV, could be responsible for the pharmacological activity of DN by regulating the AGE-RAGE, PI3K/Akt, MAPK and NF-κB signaling pathways in diabetic complications. ConclusionsThese results showed that DBT may improve DN by affecting insulin resistance, chronic inflammation and lipid accumulation.

Podocalyxin as an early marker predicting diabetic nephropathy and its correlation with stages of diabetic nephropathy in type two diabetic patients

Abstract Background Nephropathy, a major complication of diabetes, is the leading cause of end-stage renal disease. Early identification of nephropathy in diabetes patients is crucial because it creates opportunity for preventing the incidence of DN and/or even slows down the process of end-stage renal disease attributed to diabetes. Human podocytes (Pods) have been demonstrated to be functionally and structurally injured in the natural history of diabetic nephropathy. Aim of the Work To evaluate the possible association between the urinary podocalyxin levels and severity and grade of diabetic nephropathy and to use urinary podocalyxin as a non-invasive marker for early stage of diabetic nephropathy in type 2 DM. Patients and Methods We collected 60 known clinically and biochemically type 2 diabetic patients.20 diabetic patients with no evidence of diabetic nephropathy, 20 patients diagnosed as diabetic nephropathy in microalbuminuria stages and 20 patients diagnosed as diabetic nephropathy in macroalbuminuria stages from Ain Shams University hospitals between April and December 2018 and 20 apparently healthy volunteers will included as a control group. Results Urinary PCX was significantly higher in patients group compared to control group. Urinary PCX was significantly higher in microalbuminuric group than in normoalbuminuric group and higher in macroalbuminuric group than in microalbuminuric group. There was a positive significant correlation between FBS, 2HrPP, HBA1C and urinary PCX. There was a positive significant correlation between s.create and urinary PCX. There was a positive significant correlation between ACR and urinary PCX. Conclusion Urinary podocalyxin seems to be beneficial as an early marker for early stages of diabetic nephropathy in type 2 DM patients.

Study of MicroRNA192 as an Early Marker of Nephropathy in Type 2 Diabetic Patients

Study of MicroRNA192 as an Early Marker of Nephropathy in Type 2 Diabetic Patients

Empagliflozin (SGLT-2 Inhibitor) Ameliorates Early Features of Diabetic Retinopathy and Nephropathy in Type 2 Diabetic Mice Model via the Klotho Protein

Empagliflozin (SGLT-2 Inhibitor) Ameliorates Early Features of Diabetic Retinopathy and Nephropathy in Type 2 Diabetic Mice Model via the Klotho Protein

Advanced Glycation End Products and Malondialdehyde Serum Level Association with Nephropathy in Type Two Diabetic Patients

Aim of the Study: Evaluate the relation of serum level of AGEs and MDA with the development ofdiabetic nephropathy in patient with type two diabetes mellitus and to evaluate the possible mechanismby which AGEs and MDA induce nephrotic complication in type two diabetic patients.Patients and Methods: This case-control study was carried out in Erbil city from the period startedfrom 1st of December 2020 to the end of March 2021. The study included 62 type 2 diabetic patients(31 patients nephropathy and 31 patients T2DM without nephropathy), their age between 40– 69 years,these patients who attended Rizgari General Hospital. The study also included 28 healthy controlindividuals defended as subjects who apparently haven’t any chronic diseases. Blood was collectedfrom each for determination of HbA1c level , AGE3 and MDA and RBS.Results: The study revealed that, the highest mean of RBS and HbA1c was recorded in DN groupfollowed by diabetic non-nephropathy and the control group. The study revealed that, the highest meanof UACR was recorded in DN group (258.6±28.56 mg/gm) followed by diabetic non-nephropathy(35.6±11.95 mg/gm) and the control group (20.39±1.72 mg/gm) (P&lt;0.001). The study showed asignificant positive of AGEs and MDA with each of duration of DM, blood sugar, HbA1c and UACR.Conclusions: This study showed elevated of AGEs, MDA and Poor glycemic control were associatedwith diabetic nephropathy.

Connection between the Plasma Level of Apelin and Diabetic Nephropathy in Type 2 Diabetic Patients. A Case Control Study.

Background:Apelin is an adipokine that may have an advantageous role in the prediction of early diabetic nephropathy. A few studies on apelin in diabetes have been performed and this research was performed to establish the connection between the apelinergic system and diabetic nephropathy.Materials and Methods:The research included 60 patients with type 2 diabetes mellitus (T2DM) who were equally divided into Group-I (diabetic nephropathy) and Group-II (non-diabetic nephropathy), and 30 healthy subjects in the control group (Group-III). Body mass index (BMI) and waist circumference were calculated. FBG, 2 h–PPG, HbA1c, fasting lipids, urea, creatinine, eGFR, urine analysis, A/C ratio, and apelin levels were assessed.Results:A statistically significant between-group difference in plasma apelin levels was found (P < 0.001). Apelin was the highest in Group-I than in Group-II relative to Group-III (325.79 ± 59.42 pg/mL, 162.83 ± 29.88 pg/mL, and 77.43 ± 8.44 pg/mL, respectively). Among diabetic patients, plasma apelin had a significantly positive correlation with disease duration (r = 0.612), SBP (r = 0.427), DBP (r = 0.466), weight (r = 0.372), and height (r = 0.372), FBG (r = 0.684), 2 h-PPG (r = 0.744), HbA1C (r = 0.890), total (T)-cholesterol (r = 0.316), low density lipoprotein (LDL)-C (r = 0.397), urea (r = 0.575), and creatinine (r = 0.591). A significantly negative correlation was observed between plasma apelin and HDL-C (r = –0.303), and eGFR (r = –0.566).Conclusion:Apelin levels in diabetics were elevated in the case of nephropathy, impaired glucose tolerance, and dyslipidemia. This supports the relationship between the apelinergic system and diabetic nephropathy.

Evaluation of risk factors associated with nephropathy in type 2 diabetic patients in Rwanda

Evaluation of risk factors associated with nephropathy in type 2 diabetic patients in Rwanda

Assessment of Serum and Urine Neurophil Gelatinase- Associated Lipocalin (s-NGAL and u-NGAL) Level as a Predictive Factor of Disease Progression in Diabetic Nephropathy in Type 2 DM

Diabetic nephropathy (DN) is a major complication of diabetes Mellitus. Early detection and intervention of DN can slow its progression and improve patients' outcomes. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of tubular damage might become a useful biomarker for the evaluation of renal involvement in diabetic patients. We aimed to evaluate the serum and urine NGAL(s-NGAL and u-NGAL) in type 2 diabetic patients and its correlation with different stages of diabetic nephropathy. This cross-sectional study was designed on 198 subjects consisted of 50 controls and 148 type 2 diabetes patients (50 normoalbuminuric, 58 microalbuminuric, and 40 macroalbuminuric). The study was conducted with measuring s-NGAL and u-NGAL, albumin and spot urine creatinine were also measured. A highly increased level of s-NGAL was detected in macroalbuminuric group compared with controls, normoalbuminurics and microalbuminurics (P < .01). Highly raised u-NGAL levels were observed in macroalbuminurics in comparison with controls (P < .01). ROC curve demonstrated the best sensitivity and specificity of s-NGAL/u-NGAL for the macroalbuminuric state (sensitivity, 26% and 60%; specificity, 98% and 72%; respectively), in which the best cut-off points for the detection of macroalbuminuric state for s-NGAL/u-NGAL were 300 ng/mL and 71.4 ng/mL, respectively. Serum and urine-NGAL are elevated in type 2 diabetic patients, with or without albuminuria, s-NGAL level clearly correlates with severity of renal damage caused by DN and u-NGAL increases in macroalbuminuric state. S-NGAL could be a useful, noninvasive, available and practical test for evaluation of diabetic renal involvement. We could suggest u-NGAL as a probable predictor of macroalbuminuria.

Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy

The etiology of diabetic nephropathy in type 2 diabetes is multifactorial. Sustained hyperglycemia is a major contributor, but additional contributions come from the hypertension, obesity, and hyperlipidemia that are also commonly present in patients with type 2 diabetes and nephropathy. The leptin deficient BTBR ob/ob mouse is a model of type 2 diabetic nephropathy in which hyperglycemia, obesity, and hyperlipidemia, but not hypertension, are present. We have shown that reversal of the constellation of these metabolic abnormalities with leptin replacement can reverse the morphologic and functional manifestations of diabetic nephropathy. Here we tested the hypothesis that reversal specifically of the hypertriglyceridemia, using an antisense oligonucleotide directed against ApoC-III, an apolipoprotein that regulates the interactions of VLDL (very low density lipoproteins) with the LDL receptor, is sufficient to ameliorate the nephropathy of Type 2 diabetes. Antisense treatment resulted in reduction of circulating ApoC-III protein levels and resulted in substantial lowering of triglycerides to near-normal levels in diabetic mice versus controls. Antisense treatment did not ameliorate proteinuria or pathologic manifestations of diabetic nephropathy, including podocyte loss. These studies indicate that pathologic manifestations of diabetic nephropathy are unlikely to be reduced by lipid-lowering therapeutics alone, but does not preclude a role for such interventions to be used in conjunction with other therapeutics commonly employed in the treatment of diabetes and its complications.The impact of lowering lipids alone on the pathologic complications of Type 2 diabetes is unknown. Treatment with a novel antisense oligonucleotide directed against ApoC-III lowered triglycerides significantly in the leptin deficient BTBR ob/ob murine model of type 2 diabetes, but did not ameliorate hyperglycemia or improve the nephropathy.